By admin 
CureSearch for Children’s Cancer, a leading global nonprofit dedicated to accelerating the development of new pediatric cancer treatments, has announced the selection of Dr. Robbie Majzner of the Dana-Farber Cancer Institute as the recipient of the 2026 CureSearch Catapult Award. This $2 million investment, co-funded in partnership with the Jeff Gordon Children’s Foundation, is earmarked to launch a groundbreaking Phase I clinical trial for a next-generation Chimeric Antigen Receptor (CAR) T-cell therapy specifically designed to treat children and young adults with relapsed or refractory neuroblastoma. The award represents a significant milestone in the effort to overcome the biological hurdles that have historically limited the effectiveness of immunotherapy in treating solid tumors in pediatric populations.
The Critical Challenge of Relapsed Neuroblastoma
Neuroblastoma is a cancer of the sympathetic nervous system, most commonly arising in the adrenal glands, but also appearing in the chest, neck, or spinal cord. It stands as the most common extracranial solid tumor in childhood and is responsible for approximately 15% of all pediatric cancer-related deaths. While advances in multimodal therapy—including high-dose chemotherapy, surgery, radiation, and autologous stem cell transplantation—have improved initial remission rates, the prognosis for patients with high-risk or relapsed disease remains grim.
Statistically, children diagnosed with high-risk neuroblastoma face a five-year survival rate of less than 50%. For those who experience a relapse, the therapeutic options are severely limited, and long-term survival is rare. Furthermore, the intensive treatments currently employed often result in lifelong "late effects," including hearing loss, cardiac toxicity, secondary cancers, and developmental delays. The urgency for targeted, less toxic, and more effective therapies has never been greater, leading researchers to look toward the immune system for answers.
Technical Innovation: Overcoming T-Cell Exhaustion with ZAP70
The therapy developed by Dr. Majzner and his team at Dana-Farber Cancer Institute utilizes CAR T-cell technology, which involves extracting a patient’s own T-cells and genetically engineering them to express a receptor that recognizes a specific protein on cancer cells. In the case of neuroblastoma, the target is GD2, a disialoganglioside highly expressed on the surface of neuroblastoma cells but found only in limited amounts on healthy tissue.
While GD2-targeted therapies, such as monoclonal antibodies, are already part of the standard of care, CAR T-cell success in neuroblastoma has been hampered by a phenomenon known as T-cell exhaustion. Unlike blood cancers (such as B-cell acute lymphoblastic leukemia), where CAR T-cells have seen transformative success, solid tumors present a hostile microenvironment. In this environment, CAR T-cells often become "tired" or exhausted, losing their ability to proliferate and kill cancer cells shortly after administration.
To solve this, Dr. Majzner’s team has re-engineered the signaling architecture of the CAR T-cell. By incorporating a novel signaling protein called ZAP70, the researchers have created a "next-generation" CAR. In traditional CAR designs, the signaling molecules used often lead to over-activation, which paradoxically causes the cells to burn out. The inclusion of ZAP70 mimics the natural signaling process of a healthy T-cell more closely, allowing the engineered cells to remain active for longer periods, resist the immunosuppressive signals of the tumor, and sustain a more durable attack against the neuroblastoma.
Preclinical studies conducted in laboratory models have demonstrated that these ZAP70-enhanced CAR T-cells exhibit superior anti-tumor activity and significantly improved persistence compared to traditional GD2 CAR T-cell designs. The data also suggests a potentially improved safety profile, reducing the risk of rapid, overwhelming immune responses that can sometimes lead to severe side effects in patients.
Bridging the "Valley of Death" in Pediatric Research
The CureSearch Catapult Award was specifically established to address a systemic issue in medical research often referred to as the "Valley of Death." This term describes the gap between a promising laboratory discovery and the commencement of human clinical trials. Because pediatric cancers are considered "rare diseases" by pharmaceutical standards, there is often a lack of commercial incentive for private industry to fund early-stage trials for children.
By providing $2 million in critical funding, CureSearch and the Jeff Gordon Children’s Foundation are acting as a bridge, ensuring that high-potential science does not stall in the laboratory. The Catapult Award is unique in its focus on "translatability"—prioritizing projects that have a clear path to regulatory approval and clinical implementation.
The selection process for the 2026 award involved a rigorous review by CureSearch’s Scientific Advisory Council and Industry Advisory Council. These bodies, composed of experts from academia and the biotechnology industry, evaluate proposals based on their scientific merit, the urgency of the patient need, and the likelihood that the research will lead to a change in the standard of care.
A Chronology of Progress and Partnership
The development of this therapy follows a timeline of focused innovation and strategic collaboration. Dr. Majzner, a recognized leader in pediatric immunotherapy, previously conducted foundational work in CAR T-cell design at Stanford University before joining Dana-Farber. His work on GD2 targets has been a focal point of pediatric oncology research for several years.
The partnership between CureSearch and the Jeff Gordon Children’s Foundation highlights a growing trend in the nonprofit sector toward co-funding large-scale grants to maximize impact. Jeff Gordon, the four-time NASCAR Cup Series champion, established his foundation with a mission to support pediatric cancer research after witnessing the challenges faced by families in the oncology ward. This collaboration allows for the aggregation of resources necessary to fund expensive Phase I trials, which involve complex manufacturing processes for cell therapies.
With the 2026 Catapult Award, the timeline now moves toward the opening of the Phase I clinical trial. This stage will involve enrolling a small cohort of children and young adults with relapsed or refractory neuroblastoma. The primary objectives of the trial will be to determine the maximum tolerated dose of the ZAP70-GD2 CAR T-cells and to assess the safety and feasibility of the manufacturing process for each individual patient.
Official Responses and Strategic Vision
The announcement has been met with optimism from the scientific and advocacy communities. Dr. Robbie Majzner emphasized the transformative potential of the grant, noting that the limitations of previous generations of CAR T-cells have been a significant roadblock.
"Current GD2 CAR T cells only work in patients with small amounts of disease," Dr. Majzner stated. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most. The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, reinforced the organization’s commitment to clinical translation. "One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," Dr. Myers said. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
Analysis of Broader Implications and Future Impact
The success of this trial could have implications that extend well beyond neuroblastoma. GD2 is not only found in neuroblastoma but is also expressed in other difficult-to-treat pediatric cancers, including osteosarcoma (a bone cancer) and certain types of high-grade gliomas (brain tumors). If the ZAP70 signaling architecture proves successful in sustaining T-cell activity against neuroblastoma, it could serve as a blueprint for treating a wide array of GD2-expressing solid tumors in both children and adults.
Furthermore, the "next-generation" signaling approach addresses a fundamental hurdle in the entire field of oncology: making CAR T-cells work for solid tumors. While CAR T-cells have been a "miracle cure" for some leukemia patients, the broader oncology community has struggled to replicate those results in solid masses. Dr. Majzner’s research provides a potential solution to the exhaustion problem that could be adapted for other targets, such as HER2 in breast and ovarian cancers or mesothelin in pancreatic cancer.
From a regulatory and economic perspective, the Catapult Award helps de-risk the therapy. By funding the Phase I trial and gathering initial human data, CureSearch makes the project more attractive to larger pharmaceutical partners or federal funding agencies (like the National Cancer Institute) for subsequent Phase II and Phase III trials. This "de-risking" is essential for the eventual commercialization and widespread availability of the treatment.
Conclusion: A New Era for Pediatric Oncology
As the 2026 CureSearch Catapult Award moves forward, it symbolizes a shift in pediatric cancer research toward precision medicine and advanced bioengineering. By focusing on the specific biological reasons why previous therapies failed—namely T-cell exhaustion—and engineering a solution through the ZAP70 protein, Dr. Majzner and his team are pushing the boundaries of what is possible in the clinic.
For the families of children with neuroblastoma, this announcement offers more than just scientific progress; it offers the possibility of a future where a relapse is no longer a terminal diagnosis. Through the combined efforts of Dana-Farber Cancer Institute, CureSearch, and the Jeff Gordon Children’s Foundation, the path from a laboratory breakthrough to a life-saving treatment is being paved, one clinical trial at a time. The momentum generated by this $2 million investment reflects a global commitment to ensuring that no child is left behind by the progress of modern medicine.
